TerraPower Breaks Ground on Philadelphia Facility, Boosting Jobs

TerraPower Isotopes® (TPI), part of TerraPower, a nuclear innovation company that advances transformative technologies across both energy and healthcare, broke ground on its flagship Bellwether Laboratory—a 250,000-square-foot actinium-225 (Ac-225) manufacturing facility located in the Bellwether District of Philadelphia. The groundbreaking marks the next major milestone in TPI's journey to establish a state-of-the-art East Coast manufacturing presence dedicated to the production of one of the rarest and most medically promising isotopes to support the development of targeted alpha therapy and precision medicine.

"TerraPower was created to improve the world through nuclear energy and science. Breaking ground today on the Bellwether Laboratory represents a defining chapter in TerraPower's history—and in the history of actinium-225 manufacturing," said Chris Levesque, president and CEO of TerraPower. "This new flagship, state-of-the-art manufacturing facility will produce actinium-225 at a scale the industry has never seen before, providing global pharmaceutical and biotechnology companies with the reliable, large-volume supply they need to advance their clinical programs and ultimately expand cancer treatment options for patients."

"Today, TerraPower Isotopes celebrates breaking ground on the world's most advanced actinium-225 manufacturing site," said Scott Claunch, president of TerraPower Isotopes. "The Bellwether Laboratory is purpose-built to meet the needs of a growing industry that is working to transform how cancer is treated. With a highly trained and dedicated team, we are thrilled to be building our flagship facility right here in Philadelphia."